This page lists the cancer care hospitals in our directory offering Skin Cancer Treatment in Chennai, India, including Apollo Athenaa Women's Cancer Centre, Apollo Proton Cancer Centre, Apollo Hospitals, Greams Road, Gleneagles Global Hospital and others. Each listing links through to the hospital's full profile page.
Ask us about skin cancer treatment in Chennai, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 10 accredited hospitals for Cancer Care in Chennai, India
Featured🇮🇳 Apollo Athenaa Women's Cancer Centre
Ranks #1 in this list by listed rating (4.9/5 from 47 reviews).
🇮🇳 Apollo Proton Cancer Centre
Ranks #2 in this list by listed rating (4.8/5 from 213 reviews).
🇮🇳 Apollo Hospitals, Greams Road
Ranks #3 in this list by listed rating (4.7/5 from 125 reviews).
🇮🇳 Gleneagles Global Hospital
Ranks #4 in this list by listed rating (4.7/5 from 112 reviews).
🇮🇳 Dr. Rela Institute and Medical Centre
Ranks #5 in this list by listed rating (4.7/5 from 108 reviews).
🇮🇳 SIMS Hospital
Ranks #6 in this list by listed rating (4.6/5 from 20 reviews).
🇮🇳 Sankara Nethralaya
Ranks #7 in this list by listed rating (4.4/5 from 220 reviews).
🇮🇳 Apollo First Med Hospitals, Kilpauk
Ranks #8 in this list by listed rating (4.4/5 from 76 reviews).
🇮🇳 MIOT International
Ranks #9 in this list by listed rating (4.4/5 from 200 reviews).
🇮🇳 MGM Healthcare
Ranks #10 in this list by listed rating (3.7/5 from 34 reviews).
How we selected these hospitals
A hospital appears on this page when Cancer Care is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Skin Cancer Treatment in Chennai, India?
Choosing the right hospital for skin cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cancer care rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Skin Cancer Treatment
Skin cancer treatment encompasses a spectrum of evidence-based interventions — from Mohs micrographic surgery and wide local excision to immunotherapy, targeted therapy, and radiation oncology — achieving 5-year survival rates exceeding 98% for early-stage melanoma and non-melanoma subtypes when diagnosed promptly. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-licensed hospitals in Dubai and Abu Dhabi, offering world-class dermatologic oncology at a fraction of Western costs. With dedicated case management from first consultation through post-treatment surveillance, GAF Healthcare ensures seamless, medically supervised care for every stage of the skin cancer journey. Hospital Stay: 2–7 days (varies by treatment modality; Mohs surgery is often outpatient, while immunotherapy initiation or reconstructive surgery may require 3–7 days inpatient) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (surgical patients: typically 2–3 weeks post-op; systemic therapy (immunotherapy/targeted therapy) patients: 4–6 weeks to establish tolerance and confirm response before long-haul travel) • Success Rate: 95–99% (Stage I–II non-melanoma skin cancers); 85–92% (Stage I–II melanoma); 60–75% (Stage III melanoma with combined modality therapy)
Clinical Overview
Skin cancer arises from the uncontrolled proliferation of cutaneous cells, with three predominant histological subtypes: basal cell carcinoma (BCC), the most common malignancy worldwide; squamous cell carcinoma (SCC), which carries meaningful metastatic risk if neglected; and melanoma, the most aggressive form, originating from melanocytes and capable of rapid lymphatic and hematogenous spread. Additional rarer entities — Merkel cell carcinoma, dermatofibrosarcoma protuberans (DFSP), and cutaneous lymphomas — require subspecialty oncologic expertise. The physiological impact of advanced skin cancer extends well beyond the dermis: melanoma in particular exhibits a propensity to metastasize to regional lymph nodes, liver, lung, brain, and bone, triggering systemic inflammatory cascades and significant morbidity. SCC in immunocompromised patients (post-transplant recipients, HIV-positive individuals) can behave with near-melanoma aggression, necessitating vigilant multidisciplinary review. The global standard of care is governed by NCCN (National Comprehensive Cancer Network) and ESMO guidelines, stratifying management by histological subtype, tumor depth (Breslow thickness for melanoma; Clark level), perineural invasion status, margin involvement, and lymphovascular invasion. For localized BCC and SCC, Mohs micrographic surgery remains the gold standard, offering the highest cure rates (up to 99% for primary BCC) with maximal tissue conservation — a critical consideration for cosmetically sensitive sites such as the face, ears, and periorbital regions. Melanoma management is stage-driven: sentinel lymph node biopsy (SLNB) is indicated for tumors ≥0.8 mm Breslow thickness; complete lymph node dissection (CLND) or nodal observation follows based on SLNB results. Adjuvant and metastatic melanoma treatment has been revolutionized by immune checkpoint inhibitors (anti-PD-1: pembrolizumab, nivolumab; anti-CTLA-4: ipilimumab) and BRAF/MEK-targeted agents (vemurafenib/cobimetinib; dabrafenib/trametinib for BRAF V600E/K-mutant disease), achieving durable responses that were unimaginable a decade ago. Both India and the UAE have invested substantially in oncology infrastructure. Leading Indian cancer centers deploy Varian TrueBeam and Elekta linear accelerators for stereotactic radiosurgery, robotic-assisted lymph node dissection platforms, and in-house molecular pathology laboratories capable of BRAF, NRAS, c-KIT, and PD-L1 expression profiling. UAE facilities in Dubai Healthcare City (DHCC) and Abu Dhabi leverage the same technology alongside proximity to European and North American oncology networks, offering internationally credentialed tumor board consultations and clinical trial access.
Who is a Candidate?
• ELIGIBLE PATIENTS: • Histologically confirmed skin cancer (BCC, SCC, melanoma, Merkel cell carcinoma, DFSP, cutaneous T-cell lymphoma) at any stage, from in situ to Stage IV requiring systemic therapy • Patients with recurrent or incompletely excised primary tumors seeking definitive re-excision or Mohs surgery • Melanoma patients requiring sentinel lymph node biopsy (SLNB), completion lymph node dissection (CLND), or isolated limb perfusion (ILP) for regionally advanced disease • Patients with BRAF V600E/K-mutant melanoma (confirmed by molecular profiling) eligible for targeted therapy (dabrafenib + trametinib; vemurafenib + cobimetinib) • Patients with PD-L1-expressing or high tumor mutational burden (TMB-H) tumors suitable for anti-PD-1 immunotherapy (pembrolizumab, nivolumab) • Patients requiring reconstructive surgery (local flaps, skin grafts, free tissue transfer) following oncologic excision • Patients seeking adjuvant radiation therapy post-excision for high-risk SCC or melanoma with positive nodes • REQUIRED PRE-TREATMENT DIAGNOSTICS: • Full-thickness incisional or excisional skin biopsy with histopathology (H&E staining; immunohistochemistry for SOX10, S100, HMB-45, Melan-A for melanoma) • Molecular profiling panel: BRAF V600E/K, NRAS, c-KIT mutation analysis; PD-L1 expression (22C3 pharmDx assay); TMB assessment via next-generation sequencing (NGS) • Dermoscopy and, where indicated, reflectance confocal microscopy (RCM) for pre-biopsy lesion characterization • Regional lymph node ultrasound ± fine needle aspiration cytology (FNAC) • Whole-body PET-CT (FDG) for Stage IIB+ melanoma and high-risk SCC to exclude occult nodal or distant metastases • MRI brain with gadolinium contrast for Stage III–IV melanoma (baseline and surveillance) • CT chest/abdomen/pelvis with contrast for staging of regional and metastatic disease • LDH (lactate dehydrogenase) — an independent prognostic biomarker in metastatic melanoma • CBC, comprehensive metabolic panel, thyroid function tests (baseline for immunotherapy), and hepatitis B/C/HIV serology • ECOG Performance Status assessment and dermatology/oncology multidisciplinary tumor board review • CONTRAINDICATIONS / RELATIVE CONTRAINDICATIONS: • Severe autoimmune disease (active Crohn's disease, SLE, autoimmune hepatitis) — relative contraindication to anti-PD-1/CTLA-4 immunotherapy due to immune-related adverse event (irAE) risk • Active systemic infection or uncontrolled sepsis precluding surgery or immunosuppressive-adjacent therapy • ECOG Performance Status ≥3 for high-intensity systemic regimens; palliative intent should be discussed • Prior severe hypersensitivity to checkpoint inhibitors or BRAF/MEK inhibitors without rechallenge protocol in place • Organ transplant recipients on calcineurin inhibitors — immunotherapy carries substantial rejection risk; specialist transplant-oncology co-management required • Pregnancy (relative contraindication for systemic targeted/immune therapy; surgery generally permissible with obstetric co-management)
Treatment Options & Approaches
SURGICAL APPROACHES: 1. Mohs Micrographic Surgery (MMS): The oncologic gold standard for high-risk BCC and SCC in cosmetically or functionally critical anatomic sites (H-zone of the face, ears, nose, eyelids, lips, genitalia, hands, feet). The procedure involves sequential horizontal tissue excision with immediate intraoperative frozen-section margin analysis — processing 100% of the peripheral and deep surgical margins (versus the 1–2% sampled by bread-loafing in standard excision). Each stage is mapped, color-coded, and processed in a cryostat on-site. Cure rates: 99% for primary BCC, 97% for recurrent BCC, 95–97% for primary SCC. Typically performed under local anesthesia as a same-day outpatient procedure. 2. Wide Local Excision (WLE): Standard surgical approach for melanoma, with margins defined by Breslow thickness per NCCN guidelines (in situ: 0.5–1 cm; ≤1 mm: 1 cm; 1.01–2 mm: 1–2 cm; >2 mm: 2 cm). Performed under local or general anesthesia depending on lesion size and location; may require reconstructive closure with primary repair, split-thickness skin grafting (STSG), or local advancement/rotation/transposition flaps. 3. Sentinel Lymph Node Biopsy (SLNB): Indicated for melanoma ≥0.8 mm Breslow thickness (or ≥0.6 mm with adverse features: ulceration, mitotic rate ≥2/mm², lymphovascular invasion). Technetium-99m nanocolloid lymphoscintigraphy maps the sentinel node basin pre-operatively; intraoperative gamma probe + isosulfan blue/Patent Blue dye identifies the sentinel node(s) for excision. Pathological assessment by step-serial sectioning with H&E and S100/HMB-45 IHC. SLNB provides critical prognostic staging and guides adjuvant therapy decisions. 4. Completion Lymph Node Dissection (CLND) / Therapeutic Lymph Node Dissection (TLND): CLND (dissection of the entire regional nodal basin following a positive SLNB) has evolved in practice following the MSLT-II trial, which demonstrated that observation with ultrasound surveillance is non-inferior to routine CLND for disease-specific survival in many patients. TLND remains standard for clinically palpable nodal disease. 5. Isolated Limb Perfusion (ILP) / Isolated Limb Infusion (ILI): Used for in-transit melanoma metastases or unresectable regionally advanced extremity SCC. ILP employs extracorporeal perfusion of the affected limb with hyperthermic (38–40°C) melphalan ± tumor necrosis factor-alpha (TNF-α), achieving high regional drug concentrations with systemic isolation via tourniquet. Complete response rates of 40–80% reported. 6. Robotic-Assisted Surgery: Minimally invasive robotic platforms (da Vinci Surgical System) are increasingly utilized for deep cervical lymph node dissections, parotidectomy in head-and-neck SCC, and reconstructive microsurgery, offering enhanced dexterity, tremor filtration, and 3D magnification in anatomically confined dissection planes. RADIATION THERAPY: 7. External Beam Radiotherapy (EBRT): Definitive or adjuvant radiotherapy for non-surgical candidates or high-risk SCC/BCC with perineural invasion, bone involvement, or positive/close margins. Modern delivery via IMRT (Intensity-Modulated Radiation Therapy) or VMAT (Volumetric Modulated Arc Therapy) using Varian TrueBeam or Elekta Versa HD linacs, enabling precise dose sculpting to minimize salivary gland, ocular, and neural toxicity. 8. Stereotactic Radiosurgery (SRS) / Stereotactic Body Radiotherapy (SBRT): For oligometastatic melanoma brain metastases, Gamma Knife (Leksell) or CyberKnife delivers ablative-dose radiation (15–24 Gy in 1–5 fractions) with sub-millimeter accuracy, frequently replacing whole-brain radiotherapy and preserving neurocognitive function. 9. Superficial/Orthovoltage Radiotherapy & Brachytherapy: For elderly patients or those who refuse surgery, superficial X-ray therapy or HDR brachytherapy (mold technique) offers effective local control for small BCC/SCC with acceptable cosmesis. SYSTEMIC & TARGETED THERAPIES: 10. Immune Checkpoint Inhibitors (ICI): • Anti-PD-1 monotherapy: Pembrolizumab (KEYTRUDA®, 200 mg IV Q3W or 400 mg Q6W) and nivolumab (OPDIVO®, 240 mg Q2W or 480 mg Q4W) — first-line for unresectable/metastatic melanoma and high-risk adjuvant melanoma; also approved for advanced Merkel cell carcinoma (avelumab, pembrolizumab) and advanced SCC (cemiplimab, pembrolizumab) • Combination ICI: Nivolumab + ipilimumab (CheckMate 067 regimen) for metastatic melanoma — superior PFS and OS vs. monotherapy, at the cost of higher irAE rates (~55% Grade 3–4) • Relatlimab + nivolumab (OPDUALAG®): Novel LAG-3/PD-1 dual blockade approved for unresectable/metastatic melanoma, demonstrating improved PFS over nivolumab alone in RELATIVITY-047 11. BRAF/MEK-Targeted Therapy (for BRAF V600-mutant melanoma, ~50% of cutaneous melanomas): • Dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor): COMBI-d/v trials — 64% ORR, median PFS ~11 months; also approved in adjuvant setting (COMBI-AD trial) • Vemurafenib + cobimetinib; encorafenib + binimetinib (COLUMBUS trial — longest PFS in BRAF-targeted therapy class) 12. Hedgehog Pathway Inhibitors (for advanced/metastatic BCC): • Vismodegib (ERIVEDGE®) and sonidegib (ODOMZO®): SMO inhibitors blocking aberrant Hedgehog signaling — first-line for locally advanced unresectable or metastatic BCC; ORR ~43–60% for locally advanced disease 13. EGFR Inhibitors & Chemotherapy: • Cetuximab (anti-EGFR monoclonal antibody) for advanced/metastatic SCC in platinum-ineligible patients • Conventional cytotoxic chemotherapy (carboplatin, paclitaxel, dacarbazine) reserved for ICI/targeted therapy-refractory disease 14. Electrochemotherapy (ECT): Combination of IV or intratumoral bleomycin with short high-voltage electrical pulses (electroporation) to enhance intracellular drug uptake — highly effective palliative option for skin-surface melanoma/SCC metastases not amenable to surgery PHOTODYNAMIC THERAPY (PDT) & TOPICAL THERAPIES: • PDT with aminolevulinic acid (ALA) or methyl-aminolevulinate (MAL) cream + red light activation: First-line for superficial BCC, Bowen's disease (SCC in situ), and actinic keratoses; excellent cosmesis, suitable for field cancerization • Topical imiquimod (Aldara®, 5%) — Toll-like receptor 7 agonist; approved for superficial BCC and actinic keratoses • Topical 5-fluorouracil (Efudex®, 5%): For actinic keratoses and superficial BCC
Recovery
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–2 before travel): • Patient submits existing biopsy reports, dermoscopy images, histopathology slides (digitized), and imaging (PET-CT, MRI, CT) to GAF Healthcare's oncology case management team • GAF Healthcare facilitates asynchronous tumor board review by destination hospital's dermatologic oncology MDT (multidisciplinary team), with formal treatment recommendation issued within 48–72 hours • Molecular pathology review: BRAF/NRAS/c-KIT mutation status and PD-L1 expression confirmed; if profiling is incomplete, GAF arranges sample re-testing at destination laboratory • GAF Healthcare assists with e-Medical Visa application (India) or UAE entry documentation; medical invitation letter issued by treating hospital • Pre-travel checklist issued: medications to pause (anticoagulants, immunosuppressants, biologics with washout requirements), baseline blood tests to obtain locally, and fitness-to-travel clearance if needed PHASE 2 — ARRIVAL & BASELINE ASSESSMENT (Days 1–3): • Airport transfer arranged by GAF concierge; hotel/hospital accommodation confirmed for patient and attendant • Day 1: Registration, dedicated GAF patient coordinator assigned; hospital orientation and language interpreter engaged • Day 1–2: Repeat/confirmatory staging workup if required — dermoscopy, whole-body PET-CT, MRI brain (melanoma), LDH, CBC, metabolic panel, thyroid function tests (for immunotherapy candidates), ECG, anesthesia pre-assessment • Day 2–3: Formal oncology consultation; surgical and/or medical oncology review; consent process with GAF interpreter present; surgical site marking and lymphoscintigraphy mapping (if SLNB planned) PHASE 3 — SURGICAL INTERVENTION (Day 3–5, depending on staging workup timeline): • Mohs Surgery (outpatient): Procedure commences under local anesthesia; each Mohs stage takes approximately 45–60 minutes for processing; typical cases complete in 2–4 stages (3–6 hours total); same-day reconstructive closure; patient discharged same day • Wide Local Excision ± SLNB (Day Surgery / 1–2 nights): General or regional anesthesia; gamma probe-guided sentinel node identification; WLE with pre-planned margins; intraoperative frozen section if margin concern; reconstructive closure; drain placement if required; hospital stay 1–2 nights • Lymph Node Dissection / ILP (3–5 nights): More extensive procedure under general anesthesia; regional dissection (axillary, inguinal, cervical); drains in situ 3–5 days; patient mobilized Day 1 post-op • Robotic-assisted cervical or inguinal dissection: Similar stay; enhanced visualization, reduced blood loss vs. open technique PHASE 4 — INPATIENT RECOVERY & COMPLICATION SURVEILLANCE (Days 5–10 post-op): • Wound care protocol: daily nursing assessment, drain output monitoring, compression garment fitting for lymphedema prevention • Pathology results turnaround: Final histopathology (permanent sections) available 5–7 business days post-surgery; margin status, mitotic rate, lymph node involvement confirmed • MDT reconvenes to finalize adjuvant therapy plan: Adjuvant immunotherapy (pembrolizumab ×1 year post-resection per KEYNOTE-054), adjuvant targeted therapy (dabrafenib+trametinib ×1 year per COMBI-AD), or adjuvant radiotherapy as indicated • Suture/staple removal at Day 7–14 depending on wound site and tension PHASE 5 — INITIATION OF SYSTEMIC THERAPY (if applicable, Weeks 2–6): • Immunotherapy Cycle 1 administered in destination hospital under direct supervision; 6-hour observation post-infusion for infusion-related reactions • Toxicity monitoring: LFTs, thyroid function, cortisol (pituitary function), creatinine, CBC at Day 7 and Day 14 post-infusion • Targeted therapy (dabrafenib+trametinib) initiated as outpatient; baseline ophthalmology assessment (uveitis risk), cardiac assessment (QTc prolongation), and dermatology review (paradoxical keratoacanthoma risk) • BRAF/MEK-targeted therapy patients typically tolerant within 2–4 weeks; pyrexia (dabrafenib class effect) managed with dose interruption and paracetamol PHASE 6 — FIT-TO-FLY ASSESSMENT & DISCHARGE PLANNING (Weeks 3–6): • Surgical-only patients (Mohs, WLE without systemic therapy): Fit-to-fly typically at 2–3 weeks post-op, subject to wound healing confirmation and absence of infection or hematoma • Systemic therapy patients: Fit-to-fly at 4–6 weeks, after Cycle 1 toxicity has been assessed, first response evaluation completed, and home country oncologist formally briefed with a comprehensive discharge summary • GAF Healthcare coordinates: full medical records package (digital + hard copy), radiology image CD/USB, molecular pathology reports, systemic therapy continuation prescriptions with international drug availability guidance, and next surveillance imaging schedule (PET-CT/MRI at 3-month intervals) • Return airport transfer and travel insurance documentation prepared PHASE 7 — REMOTE FOLLOW-UP WITH GAF HEALTHCARE: • GAF's telemedicine platform enables monthly virtual check-ins with destination oncologist for the first 6 months • irAE (immune-related adverse event) alert protocol: patient educated to report new onset rash, diarrhea, dyspnea, visual changes, or neurological symptoms immediately via GAF 24/7 WhatsApp oncology helpline • Annual surveillance imaging and skin examination reminders managed by GAF case coordinator
Risks to be aware of
Skin cancer treatment is generally well-tolerated when appropriately matched to tumor biology and patient fitness, but carries specific, clinically meaningful risks that patients must understand before traveling for care. Surgical risks include wound infection (2–5% for standard excision; lower for Mohs due to outpatient aseptic technique), wound dehiscence, hematoma or seroma formation (particularly after lymph node dissection), and lymphedema — a chronic, potentially disabling complication occurring in 10–40% of patients after inguinal or axillary nodal dissection, requiring lifelong compression garment use. Nerve injury is a relevant risk for cervical dissection (spinal accessory nerve — shoulder drop; marginal mandibular branch of facial nerve — lip asymmetry) and inguinal dissection (femoral nerve, lateral femoral cutaneous nerve). Cosmetic outcomes after facial Mohs surgery are generally excellent with experienced reconstruction, but scarring, pin-cushioning of flaps, or pigmentation mismatch in skin grafts may require revision procedures. Immunotherapy-specific risks (immune-related adverse events, irAEs) are the most clinically significant consideration for systemic therapy candidates. Checkpoint inhibitors can trigger autoimmune inflammation in virtually any organ system: immune-mediated dermatitis (30–40%), colitis (10–15%, potentially severe), hepatitis (5–10%), pneumonitis (3–5%), endocrinopathies — thyroiditis (20–30%), adrenal insufficiency (1–2%), hypophysitis (1–3%) — and rarer but serious neurological (Guillain-Barré, myasthenia gravis) and cardiac (myocarditis, <1% but mortality rate ~25–50% if untreated) events. High-grade irAEs require immediate corticosteroid therapy (methylprednisolone 1–2 mg/kg/day IV) and immunotherapy discontinuation; specialist oncology access during the fit-to-fly window is therefore mandatory. Combination nivolumab + ipilimumab carries Grade 3–4 irAE rates of approximately 55%, necessitating closer monitoring. Patients traveling for immunotherapy must have an established emergency oncology contact in their home country and must not book return flights before Cycle 1 toxicity has fully been assessed. BRAF/MEK-targeted therapy side effects include febrile pyrexia (dabrafenib, 28%), photosensitivity (vemurafenib), cutaneous squamous cell carcinomas or keratoacanthomas arising paradoxically (vemurafenib monotherapy, up to 25% — largely mitigated by combination MEK inhibition), retinal vein occlusion or uveitis (trametinib, rare), and QTc prolongation requiring baseline and periodic ECG monitoring. Hedgehog inhibitors (vismodegib, sonidegib) carry characteristic side effects of muscle cramps (68%), alopecia (64%), dysgeusia (55%), and weight loss, with significant teratogenicity mandating reliable contraception for patients of reproductive potential. Radiation therapy risks depend on anatomical site and dose: acute mucositis, dermatitis, and fatigue are expected; late effects include fibrosis, lymphedema, xerostomia (salivary gland irradiation), and a very small secondary malignancy risk decades later. All patients are counseled on these risks as part of GAF Healthcare's pre-departure informed consent process, and a comprehensive emergency response protocol is embedded in every patient's travel documentation.
Why GAF Healthcare
GAF Healthcare provides an end-to-end non-medical support infrastructure designed to eliminate logistical friction for international oncology patients and their families. VISA & ENTRY DOCUMENTATION — INDIA: GAF Healthcare's visa assistance team prepares and submits the complete e-Medical Visa (e-MV) application package for India-bound patients, including the formal medical invitation letter from the treating JCI/NABH-accredited hospital, supporting oncology reports, and treatment cost estimates. India's e-Medical Visa is typically approved within 3–5 business days and permits a 60-day stay with up to three entries — adequate for surgical episodes plus initial systemic therapy cycles. Visas for two attendants (family caregivers) are processed simultaneously under India's e-Medical Attendant Visa category at no additional GAF service fee. VISA & ENTRY DOCUMENTATION — UAE: The UAE offers visa-on-arrival or visa-free access for passport holders from over 50 countries (including the UK, EU Schengen zone, USA, Canada, and Australia). For GCC residents and nationals, no visa is required. Patients from other regions receive a 30- or 90-day tourist/visit visa facilitated through GAF Healthcare's UAE partner hospitals, which can issue medical NOC letters to support longer-stay visa extensions through the Dubai Health Authority (DHA) or Abu Dhabi Department of Health (DOH). All visa documentation is managed digitally with confirmation typically within 24–48 hours. AIRPORT TRANSFERS & IN-COUNTRY TRANSPORT: Private airport-to-hospital transfers are pre-arranged for patients and attendants in both destinations, using wheelchair-accessible vehicles where required. All inter-facility transfers (e.g., hospital to radiotherapy center, or to a partner diagnostic imaging facility) are scheduled and coordinated by the GAF in-country concierge team, eliminating the need for patients to navigate local transport systems. DEDICATED TRANSLATORS & CULTURAL LIAISONS: GAF Healthcare provides professional medical interpreters for Arabic, Russian, French, Swahili, Amharic, and other major languages at no additional cost for all clinical consultations, consent discussions, and discharge briefings. Cultural liaison officers are assigned to patients from GCC countries, East Africa, and Central Asia to ensure dietary, religious (Halal meal arrangements, prayer space access), and social preferences are accommodated throughout the hospital stay. ACCOMMODATION FOR PATIENTS & ATTENDANTS: For surgical-only patients discharged to hotel-based recovery, GAF Healthcare maintains preferred-rate partnerships with medically suitable hotels within 5–10 minutes of treating hospitals in Mumbai, Delhi, Chennai, Hyderabad, Dubai, and Abu Dhabi — all pre-vetted for cleanliness, elevator access, proximity to pharmacies, and 24-hour reception. For patients undergoing multi-week systemic therapy, serviced apartment arrangements with kitchenette facilities are available, enabling attendants to prepare culturally appropriate meals. Hospital guest accommodation (attendant rooms or family suites) is pre-booked by GAF at JCI-accredited facilities that offer in-room attendant stays. TELEMEDICINE & REMOTE MONITORING: GAF Healthcare's digital health platform enables pre-departure oncology consultations, real-time lab result sharing with treating oncologists, and post-departure virtual follow-ups. Patients are issued a GAF Health Passport — a secure digital document containing their full oncology records, treatment summary, molecular pathology results, and emergency contact protocols — accessible by any treating physician worldwide via a QR-coded secure link.
Common questions about Skin Cancer Treatment
What is the cost of Skin Cancer Treatment in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after skin cancer treatment?
What is the success rate of skin cancer treatment, and how does it vary by stage?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Skin Cancer Treatment in Chennai, India
Discover the Top Hospitals for Skin Cancer Treatment in Chennai, India
This page lists 10 accredited cancer care hospitals in Chennai, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about skin cancer treatment in Chennai, India
How many cancer care hospitals are listed in Chennai, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there cancer care hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for skin cancer treatment in Chennai, India.
Contact us to report an inaccuracy on this page.